Health Economics›Colorectal cancer›Advanced or metastatic disease third-line therapy

Advanced or metastatic disease third-line therapy

Colorectal cancer · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Regorafenib monotherapy Variant #06	—	R 307 423	28d	—	9.3 mo	—	—	4
FOLFIRI Variant #05	—	R 2 826	14d	5.0 mo	12.1 mo	11	R 31 090 PFS proxy	8
CapeOx Variant #01	—	R 2 384	21d	4.7 mo	—	7	R 16 689 PFS proxy	1

3 of 3 regimens shown